CAESAREA, Israel, March 19, 2017 /PRNewswire/ --
Itamar Medical Ltd. (TASE: ITMR) wishes to clarify its recent pressrelease, "An Important Recognition in the US Market for the WatchPAT™ Device" from March 16th.
Certain language in the press release mistakenly implies that the new AASM clinical practice guideline formally endorses
Itamar Medical wishes to publicly and sincerely apologize for any potential misunderstanding and inconvenience this caused to the AASM, its members or their patients.
About Itamar Medical Ltd.
Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) that develops and markets innovative diagnostic and therapy solutions for sleep breathing disorders and cardiovascular conditions.
Contact: Gilad Glick Chief Executive Officer and President T: +972-4-6177000 email@example.com
SOURCE Itamar Medical Ltd
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All